Gilead Sciences
GILD
147.10
+0.25
+0.17%
Gilead Sciences
US · GILD
#110 by market cap
Listed 1992
147.10
+0.25
+0.17%
Live - 5344 symbols - heartbeat 154s ago
· 2026-10-08 18:15
Pre-market
147.73
+0.60%
After-hours
147.26
+0.11%
Overnight
146.50
-0.24%
- Market cap
- 182.40B
- P/E (TTM)i
- -55.51
- P/Bi
- 15.42
- EPSi
- 6.78
- Div yieldi
- 2.19%
- 52W posi
- 83%
Reader sentiment
Are you bullish or bearish on GILD?
Anonymous reader poll. Unscientific, not investment advice.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company focused on HIV, liver disease, hematology, oncology, and inflammatory and respiratory conditions, selling antiviral treatments under brands including Harvoni, Biktarvy-era successors to Truvada and Atripla, and Sovaldi. Michael Riordan founded the company on June 22, 1987; it is headquartered in Foster City, California.
- Founded
- 1987
- CEO
- Mr. Daniel P. O'Day
- Employees
- 17,000
- Headquarters
- Foster City, California, United States of America
- Fiscal year end
- 12-31
- Website
- gilead.com
Company profile
- Exchange
- US
- Symbol
- GILD
- Market-cap rank
- #110
- Listing date
- 1992-01-24
- Market cap
- 182.40B
- Float cap
- 182.01B
- Shares out
- 1.24B
- Float shares
- 1.24B
Sectors & themes
CAR-T Therapy
Infectious Disease
Cancer Research
Mpox (monkeypox)
Drug Manufacturers - General
Global medical industry
Regular Savings Plan
Fractional Shares JP
Quote time 2026-10-08 18:15:34 · For reference only, not investment advice and not tailored to your situation.